🚀 VC round data is live in beta, check it out!
GeNeuro Valuation Multiples
Discover revenue and EBITDA valuation multiples for GeNeuro and similar public comparables like Nidhogg Resources Holding, Respiratorius, Gabather, Stayble Therapeutics and more.
GeNeuro Overview
About GeNeuro
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
Founded
2006
HQ
Employees
19
Website
Sectors
Financials (FY)
EV
$14M
GeNeuro Financials
GeNeuro reported last fiscal year revenue of — and negative EBITDA of ($16M).
In the same fiscal year, GeNeuro generated ($16M) in EBITDA losses and had net loss of ($17M).
GeNeuro P&L
In the most recent fiscal year, GeNeuro reported revenue of — and EBITDA of ($16M).
GeNeuro expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($16M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($17M) | XXX | XXX | XXX |
| Net Debt | — | — | $12M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
GeNeuro Stock Performance
GeNeuro has current market cap of $1M, and enterprise value of $14M.
Market Cap Evolution
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14M | $1M | — | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGeNeuro Valuation Multiples
GeNeuro trades at (0.9x) EV/EBITDA.
GeNeuro Financial Valuation Multiples
As of March 30, 2026, GeNeuro has market cap of $1M and EV of $14M.
Equity research analysts estimate GeNeuro's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GeNeuro has a P/E ratio of (0.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1M | XXX | $1M | XXX | XXX | XXX |
| EV (current) | $14M | XXX | $14M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.9x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (0.9x) | XXX | XXX | XXX |
| P/E | — | XXX | (0.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GeNeuro Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
GeNeuro Margins & Growth Rates
GeNeuro's revenue in the last fiscal year grew by —.
GeNeuro's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.
GeNeuro Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
GeNeuro Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nidhogg Resources Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Respiratorius | XXX | XXX | XXX | XXX | XXX | XXX |
| Gabather | XXX | XXX | XXX | XXX | XXX | XXX |
| Stayble Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cannovum Cannabis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GeNeuro M&A Activity
GeNeuro acquired XXX companies to date.
Last acquisition by GeNeuro was on XXXXXXXX, XXXXX. GeNeuro acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by GeNeuro
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGeNeuro Investment Activity
GeNeuro invested in XXX companies to date.
GeNeuro made its latest investment on XXXXXXXX, XXXXX. GeNeuro invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by GeNeuro
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GeNeuro
| When was GeNeuro founded? | GeNeuro was founded in 2006. |
| Where is GeNeuro headquartered? | GeNeuro is headquartered in Switzerland. |
| How many employees does GeNeuro have? | As of today, GeNeuro has over 19 employees. |
| Is GeNeuro publicly listed? | Yes, GeNeuro is a public company listed on Euronext Paris. |
| What is the stock symbol of GeNeuro? | GeNeuro trades under GNRO ticker. |
| When did GeNeuro go public? | GeNeuro went public in 2016. |
| Who are competitors of GeNeuro? | GeNeuro main competitors are Nidhogg Resources Holding, Respiratorius, Gabather, Stayble Therapeutics. |
| What is the current market cap of GeNeuro? | GeNeuro's current market cap is $1M. |
| Is GeNeuro profitable? | No, GeNeuro is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.